Acorda Therapeutics Entered into Distribution and Supply Agreements with Biopas to Commercialize Inbrija in Latin America for Parkinson's Disease
Shots:
- Acorda to receive sales-based milestones along with royalties in return for a supply of the product. Inbrija is indicated for the treatment of OFF episodes in patients with PD treated with a levodopa/dopa-decarboxylase inhibitor in the US & is expected to be available in Latin America shortly
- Biopas to get exclusive distribution rights to Inbrija in 9 countries within Latin America, including Brazil and Mexico. The collaboration strengthens Biopas’ CNS portfolio which consists of 9 original treatments for PD epilepsy, movement disorders & 3 other indications
- Acorda plans to discuss with other companies to commercialize Inbrija in additional countries. Ampyra ER tablets, 10mg are available on the market
Ref: Businesswire | Image: Acorda
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
